SC
CRL icon

Samlyn Capital’s Charles River Laboratories CRL Stock Holding History

Samlyn Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-267,300
Closed -$20.3M – 119
2016
Q1 		$20.3M Buy
+267,300
New +$19.8M 0.44% 77

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Samlyn Capital's CRL Position: Q2 2016 in Review

Samlyn Capital sold out of Charles River Laboratories (CRL) in Q2 2016, closing a stake of 267,300 shares — an estimated $20.3M sold.

Samlyn Capital first reported a position in CRL in Q1 2016 and held it in 1 quarter. The position peaked at $20.3M in Q1 2016. 286 funds tracked by Wall St. Rank hold CRL as of Q2 2016.

  • Samlyn Capital reported no remaining Charles River Laboratories position as of Q2 2016 after selling out during the quarter.
  • Samlyn Capital sold 267,300 Charles River Laboratories shares in Q2 2016, an estimated $20.3M.
  • Samlyn Capital first reported a position in Charles River Laboratories in Q1 2016 and held it in 1 quarter.
  • Samlyn Capital's Charles River Laboratories position peaked at $20.3M in Q1 2016.
  • 286 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2016.

Based on Samlyn Capital's 13F filing for Q2 2016, filed 15 Aug 2016.